Recursion Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (MXN41,803 Mil) to Dec. 2025 (MXN39,027 Mil) and
declined
from Dec. 2025 (MXN39,027 Mil) to Mar. 2026 (MXN29,715 Mil).
Recursion Pharmaceuticals's annual market cap
stayed the same
from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil) but then
increased
from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN39,027 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Recursion Pharmaceuticals's Enterprise Value for Today is MXN22,905 Mil.
Recursion Pharmaceuticals (MEX:RXRX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Recursion Pharmaceuticals Market Cap Related Terms
Recursion Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RXRX vs ABSI, GLUE, ANAB: Market Cap Comparison
For the Biotechnology subindustry, Recursion Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals (MEX:RXRX) has a Market Cap of MXN33,103 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #190 out of 1423 companies in the Biotechnology industry, placing it in the top 13.4%.
Is Recursion Pharmaceuticals' Market Cap too high?
Recursion Pharmaceuticals' current Market Cap is MXN33,103 Mil. Based on the distribution chart, Recursion Pharmaceuticals ranks #190 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Market Cap compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #190 out of 1423 companies for Market Cap. This places Recursion Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.30, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Recursion Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 121.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recursion Pharmaceuticals's current Market Cap is MXN33,103 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current Market Cap is MXN33,103 Mil. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current Market Cap is MXN33,103 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:RXRX:
Market Cap: MXN33,103 Mil
GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score
Get the complete analysis for MEX:RXRX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RXRX has been successfully added to your 
